Richard J. Hardie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Richard J. Hardie has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
G M Stern
6 shared publicationsA J Lees
5 shared publicationsA. J. Lees
Institute of Neurology
3 shared publicationsA E Harding
2 shared publicationsC Gelder
2 shared publications- Claire M. Rice
Institute of Clinical Neurosciences, University of Bristol, Bristol, UK
2 shared publications
Latest Publications
- 1 February 2019
- Published by Oxford University Press (OUP)
- p. 506-539
Neurological disorders
This chapter deals mainly with common acute and chronic neurological problems, particularly as they affect employees and job applicants. The complications of occupational exposure to neurotoxins and putative neurotoxins are also covered in so far as they relate to the fitness of an exposed employee to continue working. In addition to a few well-known and common conditions, many uncommon but distinct neurological disorders may present at work or affect work capacity. Fitness for work in these disorders will be determined by the person’s functional abilities, any co-morbid illness, the efficacy or side effects of the treatment, and psychological and social factors, rather than by the precise diagnosis. This will also need to be put into the context of the job in question, as the basic requirements for a manual labouring job may be completely different from something more intellectually demanding. Indeed, even an apparently precise diagnostic label such as multiple sclerosis can encompass a complete spectrum of disability, from someone who is entirely asymptomatic to another who is totally incapacitated. Furthermore, reports by general practitioners, neurologists, or neurosurgeons may describe the symptoms, signs, and investigations in detail, but without analysing functional abilities. These colleagues may also fail to appreciate the workplace hazards, the responsibilities of the employer, or what scope exists for adaptations to the job or workplace.
- 1 February 2019
- Published by Oxford University Press (OUP)
- p. 506-539
Neurological disorders
This chapter deals mainly with common acute and chronic neurological problems, particularly as they affect employees and job applicants. The complications of occupational exposure to neurotoxins and putative neurotoxins are also covered in so far as they relate to the fitness of an exposed employee to continue working. In addition to a few well-known and common conditions, many uncommon but distinct neurological disorders may present at work or affect work capacity. Fitness for work in these disorders will be determined by the person’s functional abilities, any co-morbid illness, the efficacy or side effects of the treatment, and psychological and social factors, rather than by the precise diagnosis. This will also need to be put into the context of the job in question, as the basic requirements for a manual labouring job may be completely different from something more intellectually demanding. Indeed, even an apparently precise diagnostic label such as multiple sclerosis can encompass a complete spectrum of disability, from someone who is entirely asymptomatic to another who is totally incapacitated. Furthermore, reports by general practitioners, neurologists, or neurosurgeons may describe the symptoms, signs, and investigations in detail, but without analysing functional abilities. These colleagues may also fail to appreciate the workplace hazards, the responsibilities of the employer, or what scope exists for adaptations to the job or workplace.
- 1 January 2013
- Published by Oxford University Press (OUP)
- p. 102-131
Neurological disorders
This chapter deals mainly with common acute and chronic neurological problems, particularly as they affect employees and job applicants. The complications of occupational exposure to neurotoxins and putative neurotoxins will also be covered in so far as they relate to the fitness of an exposed employee to continue working. In addition to a few well-known and common conditions, many uncommon but distinct neurological disorders may present at work or affect work capacity. Fitness for work in these disorders will be determined by the person’s functional abilities, any comorbid illness, the efficacy or side effects of the treatment, and psychological and social factors, rather than by the precise diagnosis. This will also need to be put into the context of the job in question, as the basic requirements for a manual labouring job may be completely different from something more intellectually demanding. Indeed, even an apparently precise diagnostic label such as multiple sclerosis (MS) can encompass a complete spectrum of disability, from someone who is entirely asymptomatic to another who is totally incapacitated. Similarly, the job title ‘production operative’ may be applied to someone who is sedentary or who undertakes heavy manual handling. Furthermore, reports by general practitioners, neurologists, or neurosurgeons may describe the symptoms, signs, and investigations in detail, but without analysing functional abilities. These colleagues may also fail to appreciate the workplace hazards, the responsibilities of the employer, or what scope exists for adaptations to the job or workplace.
- 1 January 2013
- Published by Oxford University Press (OUP)
- p. 102-131
Neurological disorders
This chapter deals mainly with common acute and chronic neurological problems, particularly as they affect employees and job applicants. The complications of occupational exposure to neurotoxins and putative neurotoxins will also be covered in so far as they relate to the fitness of an exposed employee to continue working. In addition to a few well-known and common conditions, many uncommon but distinct neurological disorders may present at work or affect work capacity. Fitness for work in these disorders will be determined by the person’s functional abilities, any comorbid illness, the efficacy or side effects of the treatment, and psychological and social factors, rather than by the precise diagnosis. This will also need to be put into the context of the job in question, as the basic requirements for a manual labouring job may be completely different from something more intellectually demanding. Indeed, even an apparently precise diagnostic label such as multiple sclerosis (MS) can encompass a complete spectrum of disability, from someone who is entirely asymptomatic to another who is totally incapacitated. Similarly, the job title ‘production operative’ may be applied to someone who is sedentary or who undertakes heavy manual handling. Furthermore, reports by general practitioners, neurologists, or neurosurgeons may describe the symptoms, signs, and investigations in detail, but without analysing functional abilities. These colleagues may also fail to appreciate the workplace hazards, the responsibilities of the employer, or what scope exists for adaptations to the job or workplace.
- 24 February 2012
- Published by Springer Nature in Journal of Neurology
- Vol. 259 (5) , 995-1000
Brain biopsy in benign neurological disease
Brain biopsy is well established in clinical practice when there is suspicion of CNS malignancy. However, there is little consensus regarding the indications for brain biopsy in non-malignant neurological disease. This is due in no small part to limitations in the available literature pertaining to diagnostic brain biopsies. The published evidence largely comprises small, retrospective, single-centre analyses performed over long time periods, including non-homogeneous patient groups with considerable variation in reported outcomes. Here we present pragmatic guidance for those clinicians considering diagnostic brain biopsy in a patient with non-neoplastic neurological disease and highlight practice points with the aim of maximising the probability of gaining clinically useful information from the procedure.
- 24 February 2012
- Published by Springer Nature in Journal of Neurology
- Vol. 259 (5) , 995-1000
Brain biopsy in benign neurological disease
Brain biopsy is well established in clinical practice when there is suspicion of CNS malignancy. However, there is little consensus regarding the indications for brain biopsy in non-malignant neurological disease. This is due in no small part to limitations in the available literature pertaining to diagnostic brain biopsies. The published evidence largely comprises small, retrospective, single-centre analyses performed over long time periods, including non-homogeneous patient groups with considerable variation in reported outcomes. Here we present pragmatic guidance for those clinicians considering diagnostic brain biopsy in a patient with non-neoplastic neurological disease and highlight practice points with the aim of maximising the probability of gaining clinically useful information from the procedure.
- 18 April 2011
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 25 (5) , 614-620
Brain biopsy in cryptogenic neurological disease
Objective. Brain biopsy is standard clinical practice when CNS malignancy is suspected. Its value has not otherwise been clearly established. We reviewed the indications for, complications and outcome of diagnostic brain biopsies performed between 2003 and 2008 in a single UK centre. Methods. Subjects were retrospectively identified using theatre log books and histopathology reports. Case records were analysed by a neurologist and neurosurgeon. Cases were excluded when the pre-operative diagnosis was clearly malignancy or infection. Results. Of all (432) brain biopsies performed, 56 were performed in 52 patients with cryptogenic neurological disease. There were no permanent deficits or deaths. Histopathological reports were classified as definitive (45%), suggestive (20%) or non-diagnostic (36%). Brain biopsy made an immediate contribution to determination of diagnosis in 55% (31 of 56) and a confident diagnosis was eventually made in 40 of 52 patients (77%). Management was altered as a consequence of biopsy in 63%. Successful biopsy of a radiologically identified target increased the proportion of biopsies considered diagnostic to 78% (odds ratio 8.9) whereas non-targeted biopsy was non-diagnostic in 71%. Although a significant proportion of patients died or had progressive disease, this was not uniformly the case; 31% stabilised and 27% improved. Conclusion. We present the highest reported frequency of brain biopsy for cryptogenic neurological disease. The risk associated with the procedure was low and the biopsy results impacted significantly upon diagnosis and management. We therefore propose that the procedure should no longer be considered one of last resort.
- 18 April 2011
- Published by Taylor & Francis in British Journal Of Neurosurgery
- Vol. 25 (5) , 614-620
Brain biopsy in cryptogenic neurological disease
Objective. Brain biopsy is standard clinical practice when CNS malignancy is suspected. Its value has not otherwise been clearly established. We reviewed the indications for, complications and outcome of diagnostic brain biopsies performed between 2003 and 2008 in a single UK centre. Methods. Subjects were retrospectively identified using theatre log books and histopathology reports. Case records were analysed by a neurologist and neurosurgeon. Cases were excluded when the pre-operative diagnosis was clearly malignancy or infection. Results. Of all (432) brain biopsies performed, 56 were performed in 52 patients with cryptogenic neurological disease. There were no permanent deficits or deaths. Histopathological reports were classified as definitive (45%), suggestive (20%) or non-diagnostic (36%). Brain biopsy made an immediate contribution to determination of diagnosis in 55% (31 of 56) and a confident diagnosis was eventually made in 40 of 52 patients (77%). Management was altered as a consequence of biopsy in 63%. Successful biopsy of a radiologically identified target increased the proportion of biopsies considered diagnostic to 78% (odds ratio 8.9) whereas non-targeted biopsy was non-diagnostic in 71%. Although a significant proportion of patients died or had progressive disease, this was not uniformly the case; 31% stabilised and 27% improved. Conclusion. We present the highest reported frequency of brain biopsy for cryptogenic neurological disease. The risk associated with the procedure was low and the biopsy results impacted significantly upon diagnosis and management. We therefore propose that the procedure should no longer be considered one of last resort.
- 1 January 2008
- Published by Springer Nature
- p. 43-51
An Update on the Hardie Neuroacanthocytosis Series
- 1 January 2008
- Published by Springer Nature
- p. 43-51
An Update on the Hardie Neuroacanthocytosis Series
- 8 July 2006
- Published by Springer Nature
- p. 31-37
Levine-Critchley Syndrome of Neuroacanthocytosis: A Clinical Review
- 8 July 2006
- Published by Springer Nature
- p. 31-37
Levine-Critchley Syndrome of Neuroacanthocytosis: A Clinical Review
- 1 December 2002
- Published by SAGE Publications in Clinical Rehabilitation
- Vol. 16 (8) , 871-877
Goal attainment scaling in evaluating a multidisciplinary pain management programme
Objective: To examine the value of Goal Attainment Scaling (GAS) as a therapeutic tool and an outcome measure in a rehabilitation programme in the management of chronic pain. Design: A prospective observational study. Setting: A 15-day pain management programme, day case or residential, in an NHS Regional rehabilitation centre. Subjects: One hundred and forty-nine consecutive patients enrolled during a 15-month period. Interventions: Multidisciplinary structured educational programme of physiotherapy, occupational therapy and clinical psychology. Main outcome measures: GAS; timed tests of physical mobility measures; McGill Pain Questionnaire (MPQ); Pain Intensity Numerical Rating Scale (NRS); Oswestry low back pain Disability Questionnaire (ODQ); General Health Questionnaire (GHQ); Pain and Impairment Relationship Scale (PAIRS). GAS and physiotherapy measures were compared with baseline data at enrolment and at discharge 15 days later. At six-month follow-up all measures were repeated. Results: significant improvements at discharge were found for GAS, and physiotherapy measures. One hundred and twelve patients returned for review at six months, when improvements were maintained for GAS, sit/stand, Pain, ODQ and GHQ. GAS was shown to be a valid measure of ability, correlating significantly with walking improvement and somewhat less with a therapist-defined measure, suggesting some ability to discriminate. Conclusions: The improvement measured by GAS showed that patients were enabled by the programme to achieve personally valued goals over a six-month period and to improve on these more than on other more conventional outcome measures.
- 1 December 2002
- Published by SAGE Publications in Clinical Rehabilitation
- Vol. 16 (8) , 871-877
Goal attainment scaling in evaluating a multidisciplinary pain management programme
Objective: To examine the value of Goal Attainment Scaling (GAS) as a therapeutic tool and an outcome measure in a rehabilitation programme in the management of chronic pain. Design: A prospective observational study. Setting: A 15-day pain management programme, day case or residential, in an NHS Regional rehabilitation centre. Subjects: One hundred and forty-nine consecutive patients enrolled during a 15-month period. Interventions: Multidisciplinary structured educational programme of physiotherapy, occupational therapy and clinical psychology. Main outcome measures: GAS; timed tests of physical mobility measures; McGill Pain Questionnaire (MPQ); Pain Intensity Numerical Rating Scale (NRS); Oswestry low back pain Disability Questionnaire (ODQ); General Health Questionnaire (GHQ); Pain and Impairment Relationship Scale (PAIRS). GAS and physiotherapy measures were compared with baseline data at enrolment and at discharge 15 days later. At six-month follow-up all measures were repeated. Results: significant improvements at discharge were found for GAS, and physiotherapy measures. One hundred and twelve patients returned for review at six months, when improvements were maintained for GAS, sit/stand, Pain, ODQ and GHQ. GAS was shown to be a valid measure of ability, correlating significantly with walking improvement and somewhat less with a therapist-defined measure, suggesting some ability to discriminate. Conclusions: The improvement measured by GAS showed that patients were enabled by the programme to achieve personally valued goals over a six-month period and to improve on these more than on other more conventional outcome measures.
- Open Access
- 1 February 2002
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 72 (2) , 150a-151
Community based rehabilitation
- 1 February 2002
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 72 (2) , 150a-151
Open AccessCommunity based rehabilitation
- 5 February 2001
- Published by Springer Nature in Journal of Neurology
- Vol. 248 (2) , 87-94
Acanthocytosis and neurological disorders
Acanthocytosis occurs because of ultrastructural abnormalities of the erythrocyte membranous skeleton resulting in reduced membrane fluidity. At least three hereditary neurological conditions are associated with it, although as yet the pathogenesis of the neurological features is unknown. In abetalipoproteinaemia, an autosomal recessive condition, vitamin E deficiency results in a progressive spinocerebellar syndrome associated with peripheral neuropathy and retinitis pigmentosa. Neuroacanthocytosis is also probably an autosomal recessive condition and is characterised by chorea, orofaciolingual dyskinesia, dysarthria, areflexia, seizures and dementia. McLeod syndrome is an X-linked recessive disorder usually presneting in males as a benign myopathy within areflexia, in association with a particular abnormality of expression of Kell blood group antigens. However, occasionally the neurological features are more severe and indistinguishable from those of neuroacanthocytosis. Recent advances in molecular genetics may assist better understanding of the disease mechanisms and the search for more effective treatment.
- 5 February 2001
- Published by Springer Nature in Journal of Neurology
- Vol. 248 (2) , 87-94
Acanthocytosis and neurological disorders
Acanthocytosis occurs because of ultrastructural abnormalities of the erythrocyte membranous skeleton resulting in reduced membrane fluidity. At least three hereditary neurological conditions are associated with it, although as yet the pathogenesis of the neurological features is unknown. In abetalipoproteinaemia, an autosomal recessive condition, vitamin E deficiency results in a progressive spinocerebellar syndrome associated with peripheral neuropathy and retinitis pigmentosa. Neuroacanthocytosis is also probably an autosomal recessive condition and is characterised by chorea, orofaciolingual dyskinesia, dysarthria, areflexia, seizures and dementia. McLeod syndrome is an X-linked recessive disorder usually presneting in males as a benign myopathy within areflexia, in association with a particular abnormality of expression of Kell blood group antigens. However, occasionally the neurological features are more severe and indistinguishable from those of neuroacanthocytosis. Recent advances in molecular genetics may assist better understanding of the disease mechanisms and the search for more effective treatment.
- 1 June 2000
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 68 (6) , 689-690
Botulinum toxin in muscle spasticity
- 1 June 2000
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 68 (6) , 689-690
Botulinum toxin in muscle spasticity